201 related articles for article (PubMed ID: 31649131)
1. EVI1 triggers metabolic reprogramming associated with leukemogenesis and increases sensitivity to L-asparaginase.
Saito Y; Sawa D; Kinoshita M; Yamada A; Kamimura S; Suekane A; Ogoh H; Matsuo H; Adachi S; Taga T; Tomizawa D; Osato M; Soga T; Morishita K; Moritake H
Haematologica; 2020 Aug; 105(8):2118-2129. PubMed ID: 31649131
[TBL] [Abstract][Full Text] [Related]
2. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs.
Bindels EM; Havermans M; Lugthart S; Erpelinck C; Wocjtowicz E; Krivtsov AV; Rombouts E; Armstrong SA; Taskesen E; Haanstra JR; Beverloo HB; Döhner H; Hudson WA; Kersey JH; Delwel R; Kumar AR
Blood; 2012 Jun; 119(24):5838-49. PubMed ID: 22553314
[TBL] [Abstract][Full Text] [Related]
3. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.
Gröschel S; Schlenk RF; Engelmann J; Rockova V; Teleanu V; Kühn MW; Eiwen K; Erpelinck C; Havermans M; Lübbert M; Germing U; Schmidt-Wolf IG; Beverloo HB; Schuurhuis GJ; Ossenkoppele GJ; Schlegelberger B; Verdonck LF; Vellenga E; Verhoef G; Vandenberghe P; Pabst T; Bargetzi M; Krauter J; Ganser A; Valk PJ; Löwenberg B; Döhner K; Döhner H; Delwel R
J Clin Oncol; 2013 Jan; 31(1):95-103. PubMed ID: 23008312
[TBL] [Abstract][Full Text] [Related]
4. EVI1 overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-AF9 rearranged acute myeloid leukemia.
Matsuo H; Kajihara M; Tomizawa D; Watanabe T; Saito AM; Fujimoto J; Horibe K; Kodama K; Tokumasu M; Itoh H; Nakayama H; Kinoshita A; Taga T; Tawa A; Taki T; Shiba N; Ohki K; Hayashi Y; Yamashita Y; Shimada A; Tanaka S; Adachi S
Haematologica; 2014 Nov; 99(11):e225-7. PubMed ID: 25015941
[No Abstract] [Full Text] [Related]
5. EVI1 drives leukemogenesis through aberrant ERG activation.
Schmoellerl J; Barbosa IAM; Minnich M; Andersch F; Smeenk L; Havermans M; Eder T; Neumann T; Jude J; Fellner M; Ebert A; Steininger M; Delwel R; Grebien F; Zuber J
Blood; 2023 Feb; 141(5):453-466. PubMed ID: 36095844
[TBL] [Abstract][Full Text] [Related]
6. Aberrant expression of ecotropic viral integration site-1 in acute myeloid leukemia and acute lymphoblastic leukemia.
Su G; Lian X; Tan D; Tao H; Liu H; Chen S; Yin H; Wu D; Yin B
Leuk Lymphoma; 2015 Feb; 56(2):472-9. PubMed ID: 24828867
[TBL] [Abstract][Full Text] [Related]
7. The shortest isoform of C/EBPβ, liver inhibitory protein (LIP), collaborates with Evi1 to induce AML in a mouse BMT model.
Watanabe-Okochi N; Yoshimi A; Sato T; Ikeda T; Kumano K; Taoka K; Satoh Y; Shinohara A; Tsuruta T; Masuda A; Yokota H; Yatomi Y; Takahashi K; Kitaura J; Kitamura T; Kurokawa M
Blood; 2013 May; 121(20):4142-55. PubMed ID: 23547050
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia.
Vázquez I; Maicas M; Cervera J; Agirre X; Marin-Béjar O; Marcotegui N; Vicente C; Lahortiga I; Gomez-Benito M; Carranza C; Valencia A; Brunet S; Lumbreras E; Prosper F; Gómez-Casares MT; Hernández-Rivas JM; Calasanz MJ; Sanz MA; Sierra J; Odero MD
Haematologica; 2011 Oct; 96(10):1448-56. PubMed ID: 21750091
[TBL] [Abstract][Full Text] [Related]
9. All-trans retinoic acid enhances, and a pan-RAR antagonist counteracts, the stem cell promoting activity of EVI1 in acute myeloid leukemia.
Nguyen CH; Bauer K; Hackl H; Schlerka A; Koller E; Hladik A; Stoiber D; Zuber J; Staber PB; Hoelbl-Kovacic A; Purton LE; Grebien F; Wieser R
Cell Death Dis; 2019 Dec; 10(12):944. PubMed ID: 31822659
[TBL] [Abstract][Full Text] [Related]
10. Induction of the proapoptotic tumor suppressor gene Cell Adhesion Molecule 1 by chemotherapeutic agents is repressed in therapy resistant acute myeloid leukemia.
Fisser MC; Rommer A; Steinleitner K; Heller G; Herbst F; Wiese M; Glimm H; Sill H; Wieser R
Mol Carcinog; 2015 Dec; 54(12):1815-9. PubMed ID: 25491945
[TBL] [Abstract][Full Text] [Related]
11. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.
Fenouille N; Bassil CF; Ben-Sahra I; Benajiba L; Alexe G; Ramos A; Pikman Y; Conway AS; Burgess MR; Li Q; Luciano F; Auberger P; Galinsky I; DeAngelo DJ; Stone RM; Zhang Y; Perkins AS; Shannon K; Hemann MT; Puissant A; Stegmaier K
Nat Med; 2017 Mar; 23(3):301-313. PubMed ID: 28191887
[TBL] [Abstract][Full Text] [Related]
12. Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration.
Haas K; Kundi M; Sperr WR; Esterbauer H; Ludwig WD; Ratei R; Koller E; Gruener H; Sauerland C; Fonatsch C; Valent P; Wieser R
Genes Chromosomes Cancer; 2008 Apr; 47(4):288-98. PubMed ID: 18181178
[TBL] [Abstract][Full Text] [Related]
13. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.
Barjesteh van Waalwijk van Doorn-Khosrovani S; Erpelinck C; van Putten WL; Valk PJ; van der Poel-van de Luytgaarde S; Hack R; Slater R; Smit EM; Beverloo HB; Verhoef G; Verdonck LF; Ossenkoppele GJ; Sonneveld P; de Greef GE; Löwenberg B; Delwel R
Blood; 2003 Feb; 101(3):837-45. PubMed ID: 12393383
[TBL] [Abstract][Full Text] [Related]
14. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.
Lugthart S; van Drunen E; van Norden Y; van Hoven A; Erpelinck CA; Valk PJ; Beverloo HB; Löwenberg B; Delwel R
Blood; 2008 Apr; 111(8):4329-37. PubMed ID: 18272813
[TBL] [Abstract][Full Text] [Related]
15. Global Identification of EVI1 Target Genes in Acute Myeloid Leukemia.
Glass C; Wuertzer C; Cui X; Bi Y; Davuluri R; Xiao YY; Wilson M; Owens K; Zhang Y; Perkins A
PLoS One; 2013; 8(6):e67134. PubMed ID: 23826213
[TBL] [Abstract][Full Text] [Related]
16. High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group.
Ho PA; Alonzo TA; Gerbing RB; Pollard JA; Hirsch B; Raimondi SC; Cooper T; Gamis AS; Meshinchi S
Br J Haematol; 2013 Sep; 162(5):670-7. PubMed ID: 23826732
[TBL] [Abstract][Full Text] [Related]
17. A murine model of acute myeloid leukemia with Evi1 overexpression and autocrine stimulation by an intracellular form of GM-CSF in DA-3 cells.
Cardona ME; Simonson OE; Oprea II; Moreno PM; Silva-Lara MF; Mohamed AJ; Christensson B; Gahrton G; Dilber MS; Smith CI; Arteaga HJ
Leuk Lymphoma; 2016; 57(1):183-92. PubMed ID: 25907616
[TBL] [Abstract][Full Text] [Related]
18. Ecotropic virus integration site-1 gene preferentially expressed in post-myelodysplasia acute myeloid leukemia: possible association with GATA-1, GATA-2, and stem cell leukemia gene expression.
Ohyashiki JH; Ohyashiki K; Shimamoto T; Kawakubo K; Fujimura T; Nakazawa S; Toyama K
Blood; 1995 Jun; 85(12):3713-8. PubMed ID: 7780155
[TBL] [Abstract][Full Text] [Related]
19. Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1.
Lugthart S; Figueroa ME; Bindels E; Skrabanek L; Valk PJ; Li Y; Meyer S; Erpelinck-Verschueren C; Greally J; Löwenberg B; Melnick A; Delwel R
Blood; 2011 Jan; 117(1):234-41. PubMed ID: 20855866
[TBL] [Abstract][Full Text] [Related]
20. The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator.
Soderholm J; Kobayashi H; Mathieu C; Rowley JD; Nucifora G
Leukemia; 1997 Mar; 11(3):352-8. PubMed ID: 9067573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]